GGrantIndex
← Leaderboards

Dusan Bogunovic

Columbia University Health Sciences

$18,618,166
Attributed
$22,320,404
Total exposure
15
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.5M · FY201325
$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,804,314 · 16

By mechanism

R01$16,089,160 · 5
P01$3,311,880 · 3
R24$2,501,144 · 1
R21$932,250 · 2
R61$708,517 · 1
R00$498,000 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Genes

Research focus

GenesSignal TransductionCellsResponseInterferonsGeneticMediatingInflammationChildIn VivoInfectionInterferon Type IPredispositionRegulationCell TypeProteinsImmunologicsPathway InteractionsMolecularInflammatoryIsg15 GeneFunctional DisorderCytokineImmune

Grant awards (44)

Novel Mechanisms of Genetic Errors of Immunity$2,483,910
P01 · FY2025 · AI
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)$807,454
R24 · FY2025 · AI
Immunologic and Predictive Features of MIS-C$506,284
R01 · FY2025 · HD · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$437,310
R01 · FY2025 · AI · contact PI
Monoallelically expressed genes as a novel mechanism of genetic errors of immunity$413,985
P01 · FY2025 · AI · contact PI
Sequencing and sample core: genetic errors of immunity$413,985
P01 · FY2025 · AI · contact PI
Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome$409,397
R61 · FY2025 · AR
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)$820,780
R24 · FY2024 · AI
Next Generation Resolution of Antiviral Gene Networks$662,018
R01 · FY2024 · AI
Immunologic and Predictive Features of MIS-C$531,183
R01 · FY2024 · HD · contact PI
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes$498,911
R01 · FY2024 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$460,164
R01 · FY2024 · AI · contact PI
Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome$299,120
R61 · FY2024 · AR
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)$872,910
R24 · FY2023 · AI
Next Generation Resolution of Antiviral Gene Networks$662,018
R01 · FY2023 · AI
Immunologic and Predictive Features of MIS-C$572,109
R01 · FY2023 · HD · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$506,430
R01 · FY2023 · AI · contact PI
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes$502,255
R01 · FY2023 · AI · contact PI
Immunologic and Predictive Features of MIS-C$2,102
R01 · FY2023 · HD · contact PI
Next Generation Resolution of Antiviral Gene Networks$662,018
R01 · FY2022 · AI · contact PI
Immunologic and Predictive Features of MIS-C$610,099
R01 · FY2022 · HD · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$523,681
R01 · FY2022 · AI · contact PI
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes$502,255
R01 · FY2022 · AI · contact PI
Translational Immunology Training Program$401,225
T32 · FY2022 · AI · contact PI
Next Generation Resolution of Antiviral Gene Networks$662,018
R01 · FY2021 · AI · contact PI
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes$493,107
R01 · FY2021 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$423,750
R01 · FY2021 · AI · contact PI
Type I Interferon Dysregulation in Down Syndrome$320,158
R01 · FY2021 · AI · contact PI
Transient Gene Therapy as Broad Spectrum Antiviral$255,932
R41 · FY2021 · AI · contact PI
Next Generation Resolution of Antiviral Gene Networks$679,393
R01 · FY2020 · AI · contact PI
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes$501,657
R01 · FY2020 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$423,750
R01 · FY2020 · AI · contact PI
Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome$255,946
R01 · FY2020 · AI · contact PI
Type I Interferon Dysregulation in Down Syndrome$3,207,900
R01 · FY2019 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$423,750
R01 · FY2019 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$635,144
R01 · FY2018 · AI · contact PI
ZIKA VIRUS RESISTANCE; HOST DETERMINANTS$211,875
R21 · FY2018 · AI · contact PI
Interplay between Negative Regulators of Type I Interferon and HIV control$211,875
R21 · FY2018 · AI · contact PI
Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies$423,750
R01 · FY2017 · AI · contact PI
ZIKA VIRUS RESISTANCE; HOST DETERMINANTS$254,250
R21 · FY2017 · AI · contact PI
Interplay between Negative Regulators of Type I Interferon and HIV control$254,250
R21 · FY2017 · AI · contact PI
ISG15 responsive pathway$249,000
R00 · FY2015 · AI · contact PI
ISG15 responsive pathway$249,000
R00 · FY2014 · AI · contact PI
ISG15 responsive pathway$106,206
K99 · FY2013 · AI · contact PI